Page 164 - Drug Class Review
P. 164
Page 112 of 205
Drug Effectiveness Review Project
total 76.1 67.5 90.0% 4.4% 5.6% 7.9
placebo NR 62.7 91.3% 4.8% 3.9% NR Primary Outcome Measures: CIBIC-Plus; ADCS-ADL modified for severe dementia (ADCS-ADLsev) Secondary Outcome Measures: SIB; MMSE; GDS; FAST; NPI; Resource Utilization in Dementia; G2 MEM patients had significantly less deterioration on ADCS/ADL (difference 2.1; P = 0.02) Caregivers spent significantly less time (45.8 hours/mo) with patients receiving MEM (P = 0.01) No significant differences in GDS between placebo- and MEM-treated patients MEM was not significantly different from placebo on the CIBIC-PLUS (difference 0.3; P = 0.06
Alzheimer classification: Moderate-severe
Authors and Year: Reisberg et al. 2003; Rive et al. 2004; Doody et al. 2004
Timing of assessments: Baseline and weeks 12 and 28 FAST (P = 0.02) was significantly less deteriorated for MEM patients SIB (P = 0.002) was significantly less deteriorated for MEM patients MEM showed an advantage over all 19 items of the ADCS-ADL
Groups similar at baseline: Yes
memantine NR 72 88.9% 4.0% 7.1% NR Health Outcome Measures: No significant differences in NPI Intermediate Outcome Measures: No significant differences in MMSE Single item analysis of the ADL scales: (P < 0.05 for all 3)
scale • • • • • • • • • • •
Final Report Update 1 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other germane population qualities: MMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
